Pieris AG Appoints Chief Scientific Officer

Freising-Weihenstephan (ots) - Pieris AG announced today that
Laurent Audoly, Ph.D., has joined the company as Chief Scientific
Officer, effective immediately. Dr. Audoly, most recently Biologics
Research Site Lead at Merck & Co. Inc., brings both pharma and
biotech experience, with extensive expertise in therapeutic protein
drug development.

"Laurent has an impressive track record of leading teams and
moving discovery programs successfully from target identification
into and through the clinic. In particular, his pharmacology
expertise and drug development skills are the precise ingredients we
need to maximize the value of our growing therapeutic pipeline,"
commented Stephen Yoder, CEO of Pieris. "As the company builds and
expands its internal and partnered Anticalin pipeline, Laurent's
contribution will be significant."

"As a keen proponent of targeted therapeutic technologies, I am
excited to join Pieris at a stage where the Anticalin approach is
beginning to demonstrate its great therapeutic potential," added Dr.
Audoly. "My goal is to combine my experience from big pharma and
biotech with the capabilities present at Pieris to bring the full
spectrum of R&D operations to the next level."

Over the course of his career, Dr. Audoly has held research and
managerial positions of increasing responsibility, first as Senior
Research Scientist, Department of Inflammation, at Pfizer Inc. and
then as Senior Research Fellow, Department of Pharmacology, at Merck
& Co. Inc. He then joined MedImmune Inc. as Director R&D Inflammation
and most recently held the position at Merck and Co. Inc. as
Biologics Research Site Lead. He holds a degree in Chemistry from
the University of South Florida and a Ph.D. in Pharmacology from
Vanderbilt University. Following his studies, he completed
post-doctoral research at Duke University and the University of North
Carolina.

About Pieris

Pieris AG is an independent biotechnology company advancing its
proprietary Anticalin® technology to create safer, more efficacious
and more convenient protein therapeutics. Exclusive to Pieris,
Anticalin-based drugs promise to address high-unmet medical needs and
expand the therapeutic potential of current targeted approaches.
Pieris' pipeline ranges from its lead program (anti-VEGF, oncology),
which will enter the clinic in the first half of 2010, to multiple
Anticalins in preclinical development. Pieris will commercialize
Anticalin therapeutics through strategic partnerships, involving both
its proprietary pipeline and its de novo drug discovery capabilities.
Its most recent partnership is with Allergan, Inc. (NYSE: AGN),
focusing on novel treatments for eye diseases. Privately held,
Pieris has been funded by premier biotechnology-focused venture
capital, including lead investors OrbiMed Advisors and Global Life
Science Ventures.

Originaltext: Pieris AG
digital press kits: http://www.presseportal.de/pm/61954
press kits via RSS: http://www.presseportal.de/rss/pm_61954.rss2

For more information, please contact:
Pieris AG, Stephen Yoder, CEO, or Dr. Laurent Audoly, CSO, +49 (0)
8161 1411 400, info@pieris- ag.com